Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition

Annals of Internal Medicine

Volumn 136, Issue 8, 2002, Pages 604-615

  Remuzzi, Giuseppe ^a   Ruggenenti, Piero ^a   Perico, Norberto ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; LIPID; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM; PROTEIN; RAMIPRIL; RANTES; RENIN; SODIUM; STEROID; VASOACTIVE AGENT;

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPOPROTEINEMIA; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEINURIA; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

EID: 0037117570     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-8-200204160-00010     Document Type: Review

References (87)

1. II. Incidence and prevalence of ESRD
2. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report
3. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment
4. Structural and functional adaptation in renal failure
5. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
6. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation
7. Role for angiotensin II in an overt functional proteinuria
8. Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: A study in early passive Heymann nephritis
9. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy
10. The osmotic work of the kidney and the treatment of glomerular nephritis
11. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis
12. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulointerstitial changes
13. How far since Ellis? The Manchester Study of glomerular disease
14. The return of glomerular-filtered albumin to the rat renal vein
15. Axial heterogeneity in the handling of albumin by the rabbit proximal tubule
16. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins
17. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein
18. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation
19. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression
20. Time course and localization of endothelin-1 gene expression in a model of renal disease progression
21. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy
22. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria
23. Chemokine expression in experimental tubulointerstitial nephritis
24. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis
25. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
26. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
27. Molecular insights into renal interstitial fibrosis
28. Transforming growth factor beta in tissue fibrosis
29. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4
30. The transforming growth factor-beta system and the kidney
31. A new paracrine loop implicated in human tubulo-interstitial fibrosis: Tubular-derived endothelins modulate renal interstitial fibroblast function
32. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
33. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
34. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat
35. Passive Heymann nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury
36. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy
37. Pathophysiology of progressive nephropathies
38. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
39. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
40. Does an adequate control of blood pressure protect the kidney in essential hypertension?
41. Minimal change nephrotic syndrome-focal sclerosis complex (including IgM nephropathy and diffuse mesangial hypercellularity)
42. Nephrotic syndrome: Minimal change diseases, focal glomerulosclerosis, and related disorders
43. Persistent nephrotic syndrome: A renal biopsy study
44. Progression of "lipoid nephrosis" to renal insufficiency
45. Pathology of the nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children
46. Clinicopathological study of nephrotic syndrome in childhood
47. Natural history and outcome of the nephrotic syndrome
48. A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis
49. The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases
50. Mechanisms and functional manifestations of tubulointerstitial nephritis
51. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
52. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies
53. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
54. Effect of antihypertensive treatment on kidney function in diabetic nephropathy
55. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR
56. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy
57. Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the Captopril Study
58. Protecting single-kidney allografts from long-term functional deterioration
59. Chronic transplant rejection
60. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
61. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
62. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions
63. Progression, remission, regression of chronic renal diseases
64. The effect of high dose candesartan cilexetil beyond maximal recommended doses in reducing urinary protein excretion
65. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
66. Antiproteinuric effect of losartan in patients with chronic renal diseases
67. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively
68. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
69. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
70. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria
71. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure
72. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
73. Effects of an Ace inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
74. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition and blood pressure control on chronic, nondiabetic nephropathies
75. The risk of myocardial infarction associated with antihypertensive drug therapies
76. Blood pressure and end-stage renal disease in men
77. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
78. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis
79. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency
80. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency
81. Effect of lipid reduction on the progression of renal disease: A meta-analysis
82. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function
83. Cigarette smoking and renal function impairment
84. Smoking and the kidney
85. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons
86. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease a meta-analysis of randomized trials
87. Renoprotective therapy how good can it get?